Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients

This study is testing a new CAR-T cell therapy called CRC01 — a treatment that uses a patient's own immune cells, re-engineered in a lab to attack cancer — in adults with large B-cell lymphoma that has come back or stopped responding to previous treatments. **You may be eligible if:** - You are 19 years of age or older - You have been diagnosed with a large B-cell lymphoma (such as diffuse large B-cell lymphoma or high-grade B-cell lymphoma) - Your lymphoma has returned or stopped responding after at least two rounds of chemotherapy - You are either not eligible for, or have already tried and failed, a stem cell transplant - You are in reasonably good health (ECOG 0–1) with adequate kidney, liver, and blood cell counts **You may NOT be eligible if:** - Your lymphoma has spread to the brain or spinal fluid - You have active hepatitis B, hepatitis C, or HIV - You have previously received CAR-T or other gene therapy treatments - You are pregnant or breastfeeding - Your disease is rapidly worsening Talk to your doctor to see if this trial is right for you.